Scarica l'app Stockscreener
3.09
4.92%
-0.16
Pre-mercato:
2.93
-0.16
-5.18%
Precedente Chiudi:
$3.25
Aprire:
$3.11
Volume 24 ore:
138.51K
Relative Volume:
0.11
Capitalizzazione di mercato:
$3.34M
Reddito:
$4.96M
Utile/perdita netta:
$-6.82M
Rapporto P/E:
-0.0472
EPS:
-65.4
Flusso di cassa netto:
$-6.64M
1 W Prestazione:
-20.16%
1M Prestazione:
+24.10%
6M Prestazione:
-34.81%
1 anno Prestazione:
-38.59%
Intervallo 1D:
$3.00
$3.165
Intervallo di 1 settimana:
$3.00
$4.0253
Portata 52W:
$1.72
$15.70
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Nome
Inmed Pharmaceuticals Inc
Settore
Telefono
(604) 669-7207
Indirizzo
1445-885 WEST GEORGIA ST., VANCOUVER
Confronta INM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
3.09 | 3.34M | 4.96M | -6.82M | -6.64M | -65.40 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Inmed Pharmaceuticals Inc Borsa (INM) Ultime notizie
Inmed Pharmaceuticals Inc Amends Standby Equity Purchase Agreement With Yorkville - marketscreener.com
InMed Announces Auditor Change to CBIZ, Updates SEPA Agreement Terms | INM Stock News - Stock Titan
Transcript : InMed Pharmaceuticals Inc.Shareholder/Analyst Call - MarketScreener
Best Cannabis Stocks To Follow Now – June 2nd - Defense World
Top Premarket Gainers - MarketScreener
New CB1 and CB2 receptor modulators disclosed in Inmed patent - BioWorld MedTech
InMed Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022 - Seeking Alpha
InMed Pharmaceuticals (NASDAQ:INM) Trading Down 11.5% – Here’s What Happened - Defense World
Biotech Alert: Searches spiking for these stocks today - TipRanks
InMed Pharmaceuticals Advances Drug Pipeline Amid Financial Challenges - TipRanks
InMed Reports Third Quarter Fiscal 2025 Financial Results and Pr - GuruFocus
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update - Newsfile
InMed Pharmaceuticals Inc. SEC 10-Q Report - TradingView
SEC Form PRE 14A filed by InMed Pharmaceuticals Inc. - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
InMed Pharmaceuticals cancels special shareholder meeting By Investing.com - Investing.com Canada
InMed Pharmaceuticals cancels special shareholder meeting - Investing.com
InMed Pharmaceuticals sets date for special shareholder meeting By Investing.com - Investing.com South Africa
InMed Pharmaceuticals sets date for special shareholder meeting - Investing.com
InMed Pharmaceuticals stock hits 52-week low at $1.72 - Investing.com Australia
InMed Pharmaceuticals stock hits 52-week low at $1.72 By Investing.com - Investing.com South Africa
InMed Pharmaceuticals : Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview - MarketScreener
InMed Pharmaceuticals Stock Hits 52-Week Low at $2.34 By Investing.com - Investing.com India
InMed Pharmaceuticals Stock Hits 52-Week Low at $2.34 - Investing.com India
InMed Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
InMed Pharmaceuticals Struggles with Losses Amid Revenue Decline - MSN
InMed Pharmaceuticals Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Defense World
InMed Pharmaceuticals Board Reshuffle After Director Resignation - TipRanks
InMed to Participate in Upcoming Investor Events - Newsfile
InMed Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Yahoo Finance
InMed Pharmaceuticals Inc. (INM) reports earnings - Quartz
InMed Advances INM-089 for Dry AMD Treatment with New Intravitreal Formulation - TipRanks
Inmed selects IVT formulation of INM-089 for dry AMD - BioWorld Online
InMed advances AMD treatment with promising IVT drug formulation - MSN
Revolutionary Eye Drug INM-089 Achieves 10X Therapeutic Levels in Macular Degeneration Treatment - StockTitan
InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration - Newsfile
Inmed Pharmaceuticals Inc (INM-Q) QuotePress Release - The Globe and Mail
InMed Pharmaceuticals (NASDAQ: INM) Secures International Patent for Novel Compounds - Defense World
InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs - TipRanks
InMed Pharmaceuticals secures international patent - Investing.com India
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds - Newsfile
InMed Secures Breakthrough 20-Year Patent in Mexico for Novel Cannabinoid Compounds - StockTitan
Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise - Asianet Newsable
Inmed Pharmaceuticals Inc Azioni (INM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):